Tumor cells that generally accumulate mutations in the genome express molecules different both qualitatively and quantitatively from normal cells. An immunosurveillance system for these molecules, known as the tumor-associated antigens (TAAs), plays an important role in the elimination of cancer cells during the initial stage. Although cancer immunotherapy targeting TAAs has progressed steadily with the development of various vaccine strategies, satisfactory efficacy, such as marked tumor regression and complete response, has not been previously reported in a clinical setting. To improve the therapeutic effects of cancer immunotherapy, the application of chemokine-chemokine receptor coupling, which controls the trafficking and biodistribution of immune cells in the living body, is an attractive potential approach. This review introduces our novel "cell delivery system," which employs an Arg-Gly-Asp (RGD) fiber-mutant adenovirus vector encoding the chemokine or chemokine receptor gene in cancer immunotherapy.
The identification of T cell-recognizing tumor-associated antigens (TAAs) in human cancer, particularly in melanoma (i.e., MAGE, MART-1, gp100, tyrosinase, and TRP), facilitated the development of cancer immunotherapy based on TAA vaccination with adjuvants to elicit tumor-specific cytotoxic T lymphocytes (CTLs). In this immunologic approach to cancer, antigen-presenting cells are key vehicles for delivering TAAs and priming TAA-specific T cells, and the most potent of them is dendritic cells (DCs).
DCs express on their surface high levels of major histocompatibility complex (MHC) class I/II molecules and costimulatory molecules, all of which assist in T cell activation. 1) As shown in Fig. 1 , DCs are widely distributed over peripheral tissues, where they capture invading (exogenous) or endogenous antigens, such as bacteria, viruses, and cell debris, with full endocytotic activity characteristic of an immature state. The phenotype of DCs internalizing antigens changes to a mature state in response to these inflammatory stimuli. Subsequently, they process the antigens into the peptides presented on MHC molecules, migrate into the T cell areas of regional lymph nodes via afferent lymphatic venules, and induce primary immune responses through antigen presentation to T cells. [2] [3] [4] Because of these properties, TAAdelivered DCs are currently employed as cellular vaccines in clinical trials of cancer immunotherapy. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] However, although DC-based immunotherapy can induce and amplify the TAA-specific immune response in patients with cancer, satisfactory efficacy, such as marked tumor regression and complete response, has not been previously reported in the clinical setting. One potential cause of these disappointing results is insufficient investigation and understanding of methods that can improve the trafficking of DC vaccine from the administration site to lymphoid tissues. In addition, immune effector cells activated by TAA-presenting DC vaccine should be more efficiently accumulated in tumor tissue to injure tumor cells by cell-cell contact. Therefore innovative approaches capable of better controlling the trafficking and biodistribution of DC vaccine and immune effector cells are needed to overcome the limitations of current DC-based immunotherapy for cancer.
Chemokine-chemokine receptor coupling controls leukocytic migration and infiltration of local sites through cooperation with various cell adhesion molecules. 15) Chemokines, which are small (8-14-kDa) secreted basic proteins, comprise a superfamily that contains four subgroups: C chemokine, CC chemokine, CXC chemokine, and CX3C chemokine. 16) These subgroups are defined by the position of conservative cysteine residues in the N-terminal and interactions with their specific receptors, which belong to the superfamily of seven-transmembrane domain G-protein-coupled receptors. 17, 18) Initially, chemokines were identified as a group of cytokines capable of enhancing the migration of neutrophils and monocytes, and functional analysis has focused on their role in inflammation. In the late 1990s, the sequence of immune chemokine, which primarily affects lymphocytes and DCs, was identified by a bioinformatics technique that used an EST database search. To date, more than 50 chemokines have been identified, and they are now considered important molecules for the development of cancer immunotherapy involving the manipulation of immune cell migration and accumulation. [19] [20] [21] [22] [23] [24] [25] This review introduces our group's research for establishing a "cell delivery system" for cancer immunotherapy using an Arg-Gly-Asp (RGD) fiber-mutant adenovirus (AdRGD) vector encoding the chemokine or chemokine receptor gene.
CREATING "LYMPHOID TISSUE-DIRECTIVITY DCS" AND THEIR VACCINE EFFICACY AGAINST MELANOMA On the basis of the serial immune mechanisms shown in Fig. 1 , the degree of accumulation of administered DC vaccine in lymphoid tissues, where they present MHC class Iand II-restricted peptides to naive T cells, is a factor in deter-mining the therapeutic effects in DC-based immunotherapy. However, because optimal DC conditioning for enhancing the migratory ability has not yet been established, very few DC vaccines in currently available DC-based immunotherapies are capable of migrating from an administration site to regional lymphoid tissue. [26] [27] [28] In recent years, the identification and functional analysis of chemokines/chemokine receptors, which regulate relevant leukocyte migration and invasion into tissues, have progressed remarkably, and the chemokine-chemokine receptor coupling in DC migration from peripheral tissue to lymphoid tissue has been elucidated. Gunn et al. found that DC migration to secondary lymphoid tissues was inhibited in CC chemokine ligand-21 (CCL21) expression-defective plt/plt mice. 29) Likewise, Förster et al. reported that inhibition of DC migration to secondary lymphoid tissues occurred in CC chemokine receptor-7 (CCR7)-knockout mice. 30) Based on these results, the association between CCL21, which is produced and secreted constitutively in lymphoid tissues and lymphatic vessels, and CCR7, of which the expression is enhanced on the surface of maturing DCs, has been shown to play a central role in the control of DC migration from peripheral tissue to lymphoid tissues. Therefore if we can prepare DCs expressing CCR7 abundantly and stably on their surface for the purpose of augmentation of the migratory ability of DC vaccine toward lymphoid tissues, the efficacy of DC-based immunotherapy would be significantly improved by the promotion of priming/activation of immune effector cells (Fig. 2) . Efficient CCR7 gene transduction to DCs is proposed as a method for preparing this novel "lymphoid tissue-directivity DC" vaccine.
A vector system that can effectively deliver a foreign gene to DCs is essential for preparing a genetically modified DC vaccine. Efficient gene transduction to DCs is difficult in any conventional vector system including adenovirus (Ad) vector, which can transfect in a wide variety of cells and tissues. 31) In this regard, we succeeded in establishing highly efficient gene transduction to DCs by applying the AdRGD vector, of which the tropism was modified by insertion of the av-integrin-targeting RGD peptide into the HI-loop in their fiber knob. 32, 33) Moreover, we clarified that vaccination with DCs transduced with the TAA gene using the AdRGD vector induced considerable antitumor effects based on activation of TAA-specific CTLs in mice. 34, 35) Our results not only revealed that the AdRGD vector is useful in antigen gene delivery to DCs, but also opened up new potential for genetically modulating the immunologic functions of DCs by making use of the predominance of the AdRGD vector in gene transduction efficiency to DCs. 36) Thus we constructed AdRGD-CCR7, which carried the expression cassette containing mouse CCR7 cDNA under the control of the cytomegalovirus promoter, and confirmed vector performance. 37) CCR7 mRNA expression in CCR7-transduced DCs (CCR7/DCs) increased in a vector dose-dependent manner, and the highest levels were observed 24 h after gene transduction. On the other hand, mature DCs prepared with 1 mg/ml lipopolysaccharide (LPS)-stimulation (LPS/ DCs) and DCs transduced with luciferase-expressing control vector AdRGD-Luc (Luc/DCs) did not show an obvious change in CCR7 mRNA levels in comparison with mock (immature) DCs 24 h post-treatment. In addition, flow cytometric analysis using an anti-mouse CCR7 polyclonal anti- body showed that most CCR7/DCs, which were transduced with AdRGD-CCR7 at 50 multiplicities of infection (MOI) and then cultured for 24 h, expressed abundant CCR7 protein on their surface. Furthermore, these CCR7/DCs exhibited strong migratory ability toward CCL21, a CCR7-ligand secreted constitutively from lymphoid tissues, depending on the CCL21 concentration in a chemotaxis assay, whereas Luc/DCs, LPS/DCs, and mock DCs remained at low levels despite CCL21 stimulation (Fig. 3A) . That is, efficient CCR7-gene transduction into DCs by the AdRGD vector reinforced the surface expression of CCR7, which sensed a CCL21 concentration gradient and transmitted intracellular signals associated with migration in their original biologically active form, indicating that transduction of the chemokine receptor gene by the AdRGD vector can modify the chemokine responsiveness of DCs.
Although a technique to label DCs with radioisotopes or fluorescent substances is frequently used for evaluating the in vivo kinetics of administered DC vaccines, [38] [39] [40] [41] [42] [43] release via exosomes or leakage of the labeling material from DCs complicates the analysis. On the other hand, the use of DCs derived from enhanced green fluorescent protein-transgenic (EGFP-Tg) mice avoids this problem and enables simple evaluation and analysis of the kinetics of administered DCs without the need for labeling. Thus we investigated the migratory ability of CCR7/DCs, which were prepared from EGFP-Tg mouse-derived DCs under transductional conditions at 50 MOI followed by 24-h cultivation, using flow cytometric analysis of regional lymph node cells isolated from wild-type mice intradermally injected with them (Fig. 3B) . 37 ) At 48 h postinjection, draining lymph nodes that served as administration sites for CCR7/DCs were obviously larger than contralateral lymph nodes under macroscopic observation, and CCR7/DCs migrated approximately 5.5-and 15-fold more efficiently into the regional lymph node than Luc/DCs and mock DCs, respectively. This encouraging result clearly demonstrated that CCR7 gene transduction using the AdRGD vector is useful technology to accelerate the accumulation of DC vaccine in regional lymph nodes. To evaluate the potency of CCR7-transduced DCs as a vaccine carrier in cancer immunotherapy, we investigated anti-B16BL6 melanoma effects in mice vaccinated with DCs genetically engineered to express gp100, a melanoma-associated antigen, and CCR7 simultaneously (Fig. 4) . 37) According to our previous report, 35) obvious growth suppression of B16BL6 tumor challenge was achieved in mice vaccinated with gp100/DCs which were transduced with 25 MOI AdRGDgp100 alone, whereas immunization with mock DCs or CCR7/DCs was not effective. This vaccine efficacy of gp100/DCs depended on the administered DC dosage. Notably, equal antitumor effects were observed in groups vaccinated with 2ϫ10 5 gp100ϩCCR7/DCs, which were cotransduced with 25 MOI AdRGD-gp100 and 25 MOI AdRGD-CCR7, and with 5ϫ10 5 gp100/DCs, and vaccination with 5ϫ10 5 gp100ϩCCR7/DCs caused extensive inhibition of B16BL6 tumor growth. Moreover, we confirmed in mice at 1 week after vaccination that gp100ϩCCR7/DCs could sufficiently induce gp100-specific CTL activity using a lower The migration of DCs from administration site to lymph nodes is critical for the priming of T cells in DC-based immunotherapy. However, the poor migratory ability of antigen-delivered DCs limits the induction of a potent immune response (A). On the other hand, DCs transduced efficiently with the CCR7 gene may adequately respond to CCL21, which is constitutively released from lymphoid tissue, and acquire migratory ability to lymph nodes (B). Consequently, antigen-delivered DCs with CCR7 transduction can enhance the initiation and amplification of the T cell-dependent immune response. Fig. 3 . In Vitro Chemotaxis (A) and in Vivo Migration (B) of CCR7/DCs (A) CCR7/DCs and Luc/DCs were prepared using AdRGD-CCR7 and AdRGD-Luc (control vector), respectively, at 50 MOI, and then cultured for 24 h. In vitro chemotaxis assay was performed with a Chemotaxicell-24 installed on 24-well culture plates. CCL21 solution was added in the lower compartment at the indicated concentration, and CCR7/DCs, Luc/DCs, LPS/DCs stimulated with 1 mg/ml LPS, or mock DCs were placed in the upper chamber at 10 6 cells. After 4-h incubation, the number of cells that migrated to the lower compartment was counted. The chemotactic activity was expressed in terms of the percentage of the input cells calculated using the formula: (% of input cells)ϭ(number of migrated cells)/(number of cells placed in Chemotaxicell-24 [10 6 cells])ϫ100. (B) DCs derived from EGFP-Tg mice were transduced with AdRGD-CCR7 or AdRGD-Luc at 50 MOI and then cultured for 24 h. These transduced cells and mock DCs were intradermally injected into the left flank of wild-type C57BL/6 mice at 2ϫ10 6 cells/50 ml. Two days later, the draining inguinal lymph nodes were collected from these mice, and a single-cell suspension was prepared. The abundance of EGFP-positive DCs was assessed by flow cytometric analysis acquiring 500000 events. The number of DCs that had migrated into draining lymph nodes was calculated by multiplying the EGFP-positive DC frequency by the total number of isolated lymph node cells.
dosage than with conventional gp100/DCs. 35) These in vivo data suggest that augmentation of the lymphoid tissue-directivity of DCs by efficient CCR7 gene transduction can reduce the TAA-delivered DC vaccine dosage that is needed to elicit efficacious therapeutic effects in DC-based immunotherapy. In other words, this method may considerably reduce cost, time, and effort for DC vaccine preparation and relieve the patient from the burden of frequent blood drawing for DC isolation.
Collectively, in vivo kinetic manipulation of DC vaccine, i.e., the establishment of an active DC delivery system to lymphoid tissues, was very useful for improving the efficacy of DC-based immunotherapy. Recently, optimized DC-conditioning, which includes stimulation of antigen-presenting DCs with various cytokines or ligand-molecules, has been investigated for the development of more effective DC-based immunotherapy. Several reports demonstrated that DC stimulation with prostaglandin E 2 [44] [45] [46] or the preinduction of inflammatory response at the DC administration site 47) was effective in promoting the migration of administered DCs to lymphoid tissues. Further research and development of "lymphoid tissue-directivity DC" vaccines based on these data and our results may greatly improve efficacy and lead to the clinical application of DC-based immunotherapy.
CHEMOKINE GENE THERAPY FOR ENHANCING ACCUMULATION OF IMMUNE CELLS IN TUMOR TISSUE
Investigations of the relationship between the prognosis and the infiltration frequency of tumor-associated immune cells in patients with cancer have indicated that posttreatment recurrence or metastasis is significantly suppressed in cases that exhibit high immune cell infiltration in primary tumor tissue, [48] [49] [50] and it is widely believed that T cells represent the most potent antitumor effector cells. [51] [52] [53] On the basis of this knowledge, cancer immunotherapy research has steadily progressed toward clinical application through cooperative fundamental research and clinical studies that have developed various approaches, such as adoptive transfer of tumorspecific CTLs 54) and administration of TAA-component vaccine, 55) TAA-coding DNA vaccine, 56) genetically modified tumor cell-based vaccine, 57, 58) or TAA-delivered DC-based vaccine. [59] [60] [61] The principal objective of most conventional studies of cancer immunotherapy has been efficient induction and activation of effector cells. However, even if effector cells that exhibit the ability to kill tumor cells were adequately induced in a patient, the efficacy of cancer immunotherapy would be considerably limited if effector cells were unable to infiltrate tumor tissue and come in contact with tumor cells. Therefore innovative approaches capable of better controlling the accumulation of immune effector cells in tumor tissue are needed to overcome the limitations of current therapy and to improve the cure rate for cancer.
As shown in Fig. 5 , a concept that attempts to reinforce immune cell accumulation in tumor tissue by applying chemokines, which control the migration and infiltration of immune cells into local sites, is attractive for the development of efficacious cancer immunotherapy. We have reported that the AdRGD vector can achieve highly efficient gene transduction in various tumors as compared with other vector systems including the conventional Ad vector. [62] [63] [64] [65] [66] [67] Additionally, we constructed eight types of chemokine-expressing AdRGD vector, and demonstrated that tumor cells transduced with these AdRGD vectors could adequately secrete a biologically active chemokine, and that in vitro transfection established several chemokines as promising candidates for cancer treatment in three murine tumor models. 25, 66) Although the inoculation of chemokine-transduced tumor cells was useful for screening antitumor effects through the promotion of chemokine secretion in tumor tissue, direct in vivo injection of chemokine-expressing vector into tumor tissue is required for the development of effective chemokine genebased cancer treatment. Thus, to evaluate the potential of in vivo chemokine gene therapy for cancer using the AdRGD vector system, we investigated the tumor-suppressive effects and accumulation of tumor-associated immune cells in mice directly injected with chemokine-expressing AdRGD vector in established B16BL6 melanoma tissue. 68) This review focuses on the results of intratumoral injection of the AdRGD vector encoding the chemokine CC chemokine ligand-17 (CCL17) and CCL19.
When AdRGD-CCL17 or AdRGD-CCL19 was intratumorally injected at 3ϫ10 8 PFU (plaque-forming unit), established murine B16BL6 melanoma exhibited only slightly delayed growth compared with AdRGD-Luc (control vector)-injected tumor. In addition, on day 2 after intratumoral injection, differences in the frequency of granulocytic infiltration, size of necrotic area with undernourishment, proliferative state of tumor cells, and frequency of neovascularity were not observed among tumors injected with PBS, AdRGD-Luc, AdRGD-CCL17, and AdRGD-CCL19. These observations revealed that AdRGD vector particles themselves or the expressed chemokines, CCL17 and CCL19, did not contribute ϩ T cell infiltration in the parenchyma of tumor tissue (Fig. 6A) . Moreover, subset analysis of the T cells infiltrating into AdRGD-CCL19-injected tumors revealed that CCL19 induced significant infiltration of both CD4 ϩ and CD8 ϩ subsets, composed of helper T cells and CTLs, respectively, into tumor tissue. However, these T cells attracted by CCL19 were not in a sensitized/activated state as demonstrated by the lack of perforin-positive cells in tumors injected with AdRGD-CCL19. Significant enhancement of natural killer (NK) cell infiltration into tumor tissue was not observed in groups injected with AdRGD-CCL17 or AdRGD-CCL19. On the contrary, intratumoral injection of AdRGD-CCL17 or AdRGD-CCL19 resulted in a 16-fold or 8-fold difference in the number of NK cells in the peritumoral portion, respectively, as compared with the AdRGD-Lucinjected group (Fig. 6B) . Immunostaining against CD11c showed that intratumoral injection of each chemokineexpressing AdRGD vector could not induce significant accumulation of DCs, which are the most potent antigen-presenting cells (Fig. 3A) . Generally, the infiltration of immune cells rarely occurs in newly formed vessels in solid tumors, and immune cells that penetrate from existing blood vessels, which are present around tumor tissue, arrive at and accumulate in the tumor parenchyma through the tumor border region. 69) This explains our observation that NK cells accumulated in the tumor peripheral zone, but did not infiltrate the tumor parenchyma upon intratumoral injection of AdRGD-CCL17 or AdRGD-CCL19. On the other hand, we speculated that massive T cell infiltration occurred directly from tumor vessels in the AdRGD-CCL19-treated tumors, because a large number of T cells were observed in the center of tumor tissue as well as near the border. This theory is supported by a previous report that CCL19 increased the expression of cell adhesion molecules on vascular endothelial cells. 70) Collectively, our data demonstrate that intratumoral injection of AdRGD-CCL19 markedly promotes T cell infiltration into B16BL6 tumor tissue, and that AdRGD-CCL17 or AdRGD-CCL19 injection induces NK cell accumulation in the peritumoral area, but not inside the tumor tissue. However, because most T cells that infiltrated into the AdRGD-CCL19-injected tumor were perforin-negative, that is, in naive status, combination therapy that included another treat- 8 PFU. PBS was administered to control tumors. On day 2 after intratumoral injection, immunohistochemical staining against CD3 (pan-T marker), CD4 (helper T marker), CD8 (CTL marker), asialoGM1 (NK marker), perforin (activated T and NK marker), and CD11c (DC marker) was performed using frozen tumor sections. Then, the number of positive cells in intratumoral (A) or peritumoral (B) sections was assessed by counting six fields per specimen under ϫ400 magnification. ment, which could prime and activate these T cells, would be required for achievement of more potent anti-tumor efficacy.
We theorized that a protocol, which included intratumoral injection of the chemokine-expressing AdRGD vector combined with immunization of TAA-delivered DCs, might achieve more effective therapy for cancer by both systemic induction of TAA-specific CTLs and enhancement of their accumulation in tumor tissue. Thus we examined the antitumor effect in B16BL6-bearing mice treated with intradermal immunization of DCs transduced with gp100 by the AdRGD vector, followed by intratumoral injection of AdRGD-CCL17 or AdRGD-CCL19. 68) To confirm the activation of systemic immunity in tumor-bearing mice immunized with gp100/DCs, we evaluated CTL activity in splenocytes from these mice. Single immunization with gp100/DCs at a site distant from the tumor inoculation site could promote killing activity of effector cells targeting B16BL6 cells. Because YAC-1 cells, which are highly susceptible to NK activities, and H-2 haplotype-matched irrelevant EL4 cells were not injured by these effector cells, gp100/DC-administration could sensitize and activate gp100-specific CTLs in mice that exhibited ongoing B16BL6 tumor growth as well as in intact mice. As shown in Fig. 7A , mice injected intratumorally with PBS after gp100/DC immunization did not exhibit marked suppression of B16BL6 tumor growth as compared with gp100/DCs-untreated mice, indicating that the regression of B16BL6 tumor that had begun to proliferate was very difficult with only a single dose of gp100/DCs. At the initial stage until day 11 after intratumoral injection, tumor growth in mice treated with AdRGD-Luc after gp100/DC-immunization was obviously delayed as compared with that in the PBS-injected group. We speculated that this suppressive effect was based on the activity of immune cells, including activated CTLs, which were attracted to tumor tissue by an inflammatory response to AdRGD vector administration. In comparison with the control groups, intratumoral injection of AdRGD-CCL17 in combination with gp100/DC-immunization improved antitumor efficacy better than AdRGD-CCL19 injection. In addition, immunohistochemical analysis on day 2 after intratumoral injection of chemokine-expressing AdRGD vector revealed that AdRGD-CCL17 injection induced efficient accumulation of CD3 ϩ T cells in tumor tissue, whereas the number of T cells in tumor tissue was only slightly elevated by injection of AdRGD-CCL19 (Fig. 7B) . These data disagreed with the observation that intratumoral injection of AdRGD-CCL19 could attract a large number of T cells in mice without gp100/DC-immunization, as shown in Fig. 6A , suggesting that the responsiveness of T cells to chemokines was altered by the activation state of the host's immune system, that is, sensitization of T cells by gp100/DC-administration. These conflicting results can be explained by the evidence that CCR7, which is the corresponding receptor for CCL19, is expressed on naive T cells, but not on effector-type T cells. 71 ϩ T cells derived from the peripheral blood or tumor-involved lymph nodes of patients with stage III metastatic melanoma was significantly associated with enhanced survival. 73) Therefore the search for an effective chemokine for cancer immunotherapy needs to be performed in an experimental model that can reflect clinical status, including the immunogenicity of tumors, the state of the host's immune system, and the combination with other treatments, as much as possible.
Taken together, our results suggest that chemokine gene transduction into established tumors using the AdRGD vector could enhance the accumulation of immune cells and would contribute to the development of efficacious cancer immunogenetherapy based on an immune cell delivery system. In addition, combinational therapy that includes immunization with TAA-delivered DCs and intratumoral injection of AdRGD-CCL17 could more effectively suppress tumor growth as compared with each treatment alone, indicating that the combined treatment, which can systemically induce tumor-specific effector CTLs, is a promising strategy for potentiating antitumor efficacy by direct injection of chemokine-expressing vector into tumors.
CONCLUSION
Conventional research on cancer immunotherapy has mainly focused on the search for efficient means to prime/ activate TAA-specific immunity. Although these studies produced various vaccine strategies, a systematic understanding of the molecular basis of the trafficking and biodistribution of immune cells is important for the development of more efficacious cancer immunotherapy. In this review, I presented the "cell delivery system" using the AdRGD vector encoding the chemokine or chemokine receptor gene as a promising approach to potentiate the migration of DC vaccine into lymphoid tissue and the accumulation of immune effector cells in tumor tissue. Recent characterization of various chemokines and chemokine receptors in the immune system will not only increase our knowledge of regulatory mechanisms for the immune response and tolerance based on immune cell localization, but also facilitate the proposal of new strategies for the clinical application of cancer immunotherapy. I hope that the results of our research will contribute to the development of a new generation of cancer immunotherapy.
